Astellas Pharma Europe Ltd.

POWER SEARCH PRICING

SOLUTIONS

astellas pharma europe ltd. Company Information

Company Number

02486792

Next Accounts

Dec 2025

Directors

Richard Gane

Lesley Flowerdew

View All

Shareholders

astellas bv

Group Structure

View All

Industry

Wholesale of pharmaceutical goods

Registered Address

300 dashwood lang road, bourne business park, addlestone, KT15 2NX

Website

www.astellas.com

astellas pharma europe ltd. Estimated Valuation

£3.7b

Pomanda estimates the enterprise value of ASTELLAS PHARMA EUROPE LTD. at £3.7b based on a Turnover of £1.6b and 2.29x industry multiple (adjusted for size and gross margin).

Edit your figures and get a professional valuation report.

Astellas Pharma Europe Ltd. is a live company located in addlestone, KT15 2NX with a Companies House number of 02486792. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in March 1990, it's largest shareholder is astellas bv with a 100% stake. Astellas Pharma Europe Ltd. is a mature, mega sized company, Pomanda has estimated its turnover at £1.6b with low growth in recent years.

View Sample

Upgrade for unlimited company reports & a free credit check

Pomanda's financial health check has awarded Astellas Pharma Europe Ltd. a 3 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 6 areas for improvement. Company Health Check FAQs

Health Rating3out of 5

5 Strong

0 Regular

6 Weak

Size

annual sales of £1.6b, make it larger than the average company (£24.9m)

Growth

3 year (CAGR) sales growth of 4%, show it is growing at a slower rate (5.6%)

EXPORT

Astellas Pharma Europe Ltd.'s latest turnover from March 2024 is £1.6 billion and the company has net assets of £581.4 million. According to their latest financial statements, Astellas Pharma Europe Ltd. has 458 employees and maintains cash reserves of 0 as reported in the balance sheet.

Data source: Companies House, Pomanda Estimates

	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010
Turnover	1,633,653,718	1,466,289,597	1,187,037,199	1,465,960,776	1,344,006,648	968,564,103	1,181,980,035	1,050,128,250	897,697,170	573,027,181	379,417,297	324,477,628	327,501,174	306,394,408	537,647,113
Other Income Or Grants
Cost Of Sales	129,799,100	113,850,450	113,835,529	120,710,045	123,052,628	106,673,509	121,243,155	108,045,667	100,475,777	80,167,212	55,361,721	64,775,270	63,800,950	66,977,439	216,039,027
Gross Profit	1,503,854,618	1,352,439,146	1,073,201,669	1,345,250,731	1,220,954,020	861,890,594	1,060,736,881	942,082,583	797,221,393	492,859,969	324,055,576	259,702,358	263,700,224	239,416,969	321,608,086
Admin Expenses	1,489,254,751	1,318,872,124	1,137,798,587	957,929,590	907,907,183	859,014,753	746,972,647	652,180,758	590,627,261	436,403,418	377,035,666	303,847,669	294,521,242	245,561,500	231,093,191
Operating Profit	14,599,867	33,567,022	-64,596,918	387,321,141	313,046,837	2,875,841	313,764,234	289,901,825	206,594,132	56,456,551	-52,980,090	-44,145,311	-30,821,018	-6,144,531	90,514,895
Interest Payable	200,067	349,283	567,651	58,324	60,211		157,267	180	9,239	9,360	159,737	49,353
Interest Receivable	19,923,307	3,416,972	6,726	90,711	12,916		84,917	25,089	9,224	2,227	1,693	18,612	768,902	1,006,367	687,658
Pre-Tax Profit	120,192,564	123,605,368	-45,380,687	454,722,953	331,390,367	166,106,051	437,082,082	311,532,223	207,654,281	56,449,420	-53,138,134	-44,176,052	-30,052,117	-5,138,164	91,202,553
Tax	-10,480,994	-10,100,867	9,981,489	-36,393,277	-40,295,823	1,307,097	-34,248,700	-37,365,542	-25,716,053	-7,438,945	22,594,027	1,129,879	1,133,458	950,455	-27,601,071
Profit After Tax	109,711,571	113,504,502	-35,399,199	418,329,676	291,094,544	167,413,149	402,833,382	274,166,681	181,938,229	49,010,475	-30,544,107	-43,046,173	-28,918,659	-4,187,710	63,601,482
Dividends Paid	250,083,361		216,356,556	322,441,960		517,732,332	237,293,986	128,118,318
Retained Profit	-140,371,791	113,504,502	-251,755,754	95,887,715	291,094,544	-350,319,184	165,539,396	146,048,363	181,938,229	49,010,475	-30,544,107	-43,046,173	-28,918,659	-4,187,710	63,601,482
Employee Costs	82,287,429	78,753,751	80,401,769	64,875,805	61,324,776	57,702,153	55,754,083	55,193,331	59,330,967	49,175,978	29,467,587	29,575,811	25,922,122	21,609,131	19,839,503
Number Of Employees	458	454	420	416	413	397	399	390	369	329	273	244	232	181	161
EBITDA*	24,721,574	42,560,854	-53,075,722	403,194,607	329,192,446	6,875,442	325,628,689	302,477,341	220,352,710	66,703,863	-38,987,424	-11,215,667	-21,797,875	359,566	98,022,337

* Earnings Before Interest, Tax, Depreciation and Amortisation

	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010
Tangible Assets	9,103,867	8,288,596	21,615,768	28,333,465	31,053,176	191,297,285	33,318,930	31,164,383	33,333,947	33,056,477	25,181,108	32,076,728	24,748,480	9,309,251	6,929,132
Intangible Assets	26,400,467	31,843,114	24,396,427	15,235,089	19,841,818	22,046,852	20,050,297	23,716,372	26,196,363	27,303,835	19,673,484	96,754,423	123,444,696	87,381,101	31,974,751
Investments & Other	156,667,223	156,400,467	200,270,920	186,265,899	166,495,164		163,702,789	169,061,753	167,814,217	160,179,470		1			1
Debtors (Due After 1 year)	14,011,337	19,083,861	74,972				349,297	2,479,950	3,720,411	7,079,303	26,731,335	6,638,568	8,301,973	8,097,671	7,172,953
Total Fixed Assets	206,182,894	215,616,039	246,358,087	229,834,454	217,390,158	213,344,138	216,371,921	226,422,459	231,064,938	227,619,086	71,585,927	135,469,720	156,495,149	104,788,023	46,076,837
Stock & work in progress	57,580,027	42,685,062	60,796,378	43,336,007	29,907,897	25,402,396	18,900,290	18,959,692	11,135,068	11,296,481	8,873,420	9,024,024	7,086,640	7,898,167	4,557,886
Trade Debtors	453,827,109	391,788,096	274,314,109	7,483,628	4,447,400	8,837,685	12,153,198	12,840,567	4,856,478	8,951,871	23,491,286	6,412,087	7,309,025	5,943,520	75,522,947
Group Debtors	915,962,820	895,065,021	952,790,383	1,040,795,712	885,354,612		1,063,976,588	711,659,556	522,889,449	261,650,727	133,500,204	75,193,467	140,371,890	217,537,270	464,276,066
Misc Debtors	27,089,029	25,873,624	81,556,764	11,819,981	26,550,853		23,686,963	19,920,700	23,308,082	23,687,702	16,989,386	17,288,267	16,282,837	19,904,388	32,825,317
Cash									6,142,951	8,030,427	4,902,917	13,467,844	4,265,112	1	9,132,670
misc current assets
total current assets	1,454,458,986	1,355,411,804	1,369,457,635	1,103,435,329	946,260,763	754,551,305	1,042,715,965	763,380,515	568,332,030	313,617,210	187,757,214	121,385,690	175,315,505	251,283,347	586,314,887
total assets	1,660,641,881	1,571,027,843	1,615,815,722	1,333,269,783	1,163,650,921	967,895,442	1,259,087,886	989,802,974	799,396,968	541,236,296	259,343,142	256,855,410	331,810,654	356,071,370	632,391,724
Bank overdraft	751,917			419		96,880	92,605							3,932,209	354,660
Bank loan
Trade Creditors	426,673,891	450,735,245	355,989,178	25,489,538	6,789,687	12,280,928	8,567,315	23,037,251	15,411,382	17,518,964	15,625,915	14,340,045	10,814,487	3,502,155	10,052,855
Group/Directors Accounts		3,353,618	350,757,661	330,386,604	278,125,187		346,052,810	196,855,256	177,867,424	136,336,599	85,185,520	117,852,367	97,677,901	140,135,057	105,375,910
other short term finances						402,654,846
hp & lease commitments	1,698,066	1,937,312	1,928,626	886,279	1,167,436				607,014
other current liabilities	640,067,522	379,781,593	258,890,841	79,831,943	74,994,524			67,804,737	53,387,572	50,513,161	32,006,830	28,383,609	74,520,339	26,800,123	79,475,877
total current liabilities	1,069,191,397	835,807,769	967,566,306	436,594,784	361,076,835	472,220,783	415,504,844	287,697,244	247,273,393	204,368,724	132,818,265	160,576,021	183,012,729	174,369,545	195,259,303
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities	6,118,706	7,237,412
provisions	3,897,965	6,177,059	16,731,825	19,097,742	18,727,787		133,643	2,146,018	2,861,186		5,690,809	7,309,628	7,458,802
total long term liabilities	10,016,672	13,414,471	16,731,825	19,097,742	18,727,788	2,540,235	129,434	2,146,018	2,861,187		5,690,810	7,309,629	7,458,803
total liabilities	1,079,208,069	849,222,241	984,298,132	455,692,526	379,804,622	474,761,017	415,634,278	289,843,263	250,134,579	204,368,724	138,509,075	167,885,650	190,471,531	174,369,545	195,259,303
net assets	581,433,811	721,805,602	631,517,591	877,577,257	783,846,299	493,134,425	843,453,608	699,959,711	549,262,389	336,867,572	120,834,067	88,969,760	141,339,123	181,701,825	437,132,421
total shareholders funds	581,433,811	721,805,602	631,517,591	877,577,257	783,846,298	493,134,425	843,453,608	699,959,711	549,262,389	336,867,572	120,834,067	88,969,760	141,339,123	181,701,825	437,132,421

	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010
Operating Activities
Operating Profit	14,599,867	33,567,022	-64,596,918	387,321,141	313,046,837	2,875,841	313,764,234	289,901,825	206,594,132	56,456,551	-52,980,090	-44,145,311	-30,821,018	-6,144,531	90,514,895
Depreciation	1,039,513	1,875,625	4,421,383	5,149,940	5,651,163	3,999,601	4,535,091	5,443,815	5,720,831	4,199,351	3,048,106	4,639,455	3,657,694	1,322,690	1,102,641
Amortisation	9,082,194	7,118,206	7,099,813	10,723,526	10,494,446		7,329,364	7,131,701	8,037,747	6,047,961	10,944,560	28,290,189	5,365,449	5,181,408	6,404,801
Tax	-10,480,994	-10,100,867	9,981,489	-36,393,277	-40,295,823	1,307,097	-34,248,700	-37,365,542	-25,716,053	-7,438,945	22,594,027	1,129,879	1,133,458	950,455	-27,601,071
Stock	14,894,965	-18,111,317	17,460,371	13,428,110	4,505,501	6,502,106	-59,402	7,824,623	-161,413	2,423,061	-150,604	1,937,384	-811,526	3,340,281	4,557,886
Debtors	79,079,693	23,074,375	248,636,906	143,746,456	907,515,181	-1,091,374,282	353,660,491	192,126,352	253,404,817	100,657,392	95,179,823	-66,733,336	-79,217,125	-328,314,434	579,797,284
Creditors	-24,061,354	94,746,067	330,499,640	18,699,851	-5,491,241	3,713,614	-14,469,937	7,625,870	-2,107,582	1,893,049	1,285,869	3,525,558	7,312,333	-6,550,701	10,052,855
Accruals and Deferred Income	260,285,929	120,890,752	179,058,898	4,837,419	74,994,524		-67,804,737	14,417,165	2,874,411	18,506,331	3,623,221	-46,136,730	47,720,216	-52,675,754	79,475,877
Deferred Taxes & Provisions	-2,279,094	-10,554,766	-2,365,917	369,955	18,727,787	-133,643	-2,012,375	-715,168	2,861,186	-5,690,809	-1,618,819	-149,174	7,458,802
Cash flow from operations	154,211,403	232,578,981	198,001,111	233,533,989	-534,892,989	1,096,634,686	-146,508,149	86,488,691	-54,978,732	-29,106,964	-108,132,345	11,949,818	121,855,585	267,057,720	-424,405,172
Investing Activities
capital expenditure	-5,494,331	-3,113,347	-13,964,836	-8,547,027	146,303,535	-163,974,512	-10,352,927	-7,925,961	-12,928,576	-25,753,032	69,983,893	-13,567,619	-60,525,967	-64,290,567	-46,411,325
Change in Investments	266,755	-43,870,453	14,005,020	19,770,736	166,495,164	-163,702,789	-5,358,965	1,247,537	7,634,746	160,179,470	-1	1			1
cash flow from investments	-5,761,086	40,757,106	-27,969,856	-28,317,763	-20,191,629	-271,723	-4,993,962	-9,173,498	-20,563,322	-185,932,502	69,983,894	-13,567,620	-60,525,967	-64,290,567	-46,411,326
Financing Activities
Bank loans
Group/Directors Accounts	-3,353,618	-347,404,043	20,371,056	52,261,417	278,125,187	-346,052,810	149,197,554	18,987,832	41,530,825	51,151,079	-32,666,847	20,174,465	-42,457,156	34,759,147	105,375,910
Other Short Term Loans					-402,654,846	402,654,846
Long term loans
Hire Purchase and Lease Commitments	-239,246	8,686	1,042,347	-281,157	1,167,436			-607,014	607,014
other long term liabilities	-1,118,706	7,237,412
share issue		-23,216,491	5,696,088	-2,156,756	-382,670	1	-22,045,500	4,648,959	30,456,588	167,023,030	62,408,414	-9,323,190	-11,444,043	-251,242,886	373,530,939
interest	19,723,240	3,067,689	-560,925	32,387	-47,295		-72,350	24,909	-15	-7,133	-158,044	-30,741	768,902	1,006,367	687,658
cash flow from financing	15,011,670	-360,306,747	26,548,566	49,855,891	-123,792,188	56,602,037	127,079,704	23,054,686	72,594,412	218,166,976	29,583,523	10,820,534	-53,132,297	-215,477,372	479,594,507
cash and cash equivalents
cash								-6,142,951	-1,887,477	3,127,511	-8,564,927	9,202,732	4,265,111	-9,132,669	9,132,670
overdraft	751,917		-419	419	-96,880	4,275	92,605						-3,932,209	3,577,549	354,660
change in cash	-751,917		419	-419	96,880	-4,275	-92,605	-6,142,951	-1,887,477	3,127,511	-8,564,927	9,202,732	8,197,320	-12,710,218	8,778,010

Very Low Risk70 - 100

Low Risk50 - 70

Moderate Risk30 - 50

High Risk20 - 30

Very High Risk0 - 20

Get a comprehensive credit check for astellas pharma europe ltd.. Get real-time insights into astellas pharma europe ltd.'s credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Perform a competitor analysis for astellas pharma europe ltd. by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other mega companies, companies in KT15 area or any other competitors across 12 key performance metrics.

ASTELLAS PHARMA EUROPE LTD. group structure

Astellas Pharma Europe Ltd. has 3 subsidiary companies.

Ultimate parent company

ASTELLAS PHARMA INC

#0017018

1 parent

ASTELLAS PHARMA EUROPE LTD.

02486792

3 subsidiaries

ASTELLAS PHARMA LTD.

00787610

ASTELLAS ENGINEERED SMALL MOLECULES U.K. LIMITED

08328823

BRIPHARM LIMITED

00909478

ASTELLAS PHARMA EUROPE LTD. Shareholders

astellas bv

100%

Astellas Pharma Europe Ltd. currently has 5 directors. The longest serving directors include Mr Richard Gane (Nov 2021) and Ms Lesley Flowerdew (Apr 2022).

officer	country	age	start	end	role
Mr Richard Gane	United Kingdom	56 years	Nov 2021	-	Director
Ms Lesley Flowerdew	United Kingdom	57 years	Apr 2022	-	Director
Ms Marloes Schaddelee	United Kingdom	52 years	Jul 2022	-	Director
Ms Martina Dempsey	United Kingdom	59 years	Apr 2023	-	Director
Dr Alan McDougall	United Kingdom	62 years	Sep 2023	-	Director

P&L

March 2024

turnover

1.6b

+11%

operating profit

14.6m

-57%

gross margin

92.1%

-0.2%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

March 2024

net assets

581.4m

-0.19%

total assets

1.7b

+0.06%

cash

net assets

Total assets minus all liabilities

Similar Companies

phoenix healthcare distribution limited

4.5

bayer public limited company

4.5

glaxosmithkline export limited

glaxosmithkline uk limited

abbvie ltd

4.5

company number

02486792

Type

Private limited with Share Capital

industry

46460 - Wholesale of pharmaceutical goods

incorporation date

March 1990

ultimate parent company

ASTELLAS PHARMA INC

previous names

yamanouchi u.k. limited (May 2005)

lupinbrook limited (May 1990)

address

300 dashwood lang road, bourne business park, addlestone, KT15 2NX

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We did not find charges/mortgages relating to astellas pharma europe ltd..

When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.

Click to start generating capital raising & share issue transactions for ASTELLAS PHARMA EUROPE LTD.. This can take several minutes, an email will notify you when this has completed.

astellas pharma europe ltd. Company Information

astellas pharma europe ltd. Estimated Valuation

astellas pharma europe ltd. Estimated Valuation

astellas pharma europe ltd. Estimated Valuation

Astellas Pharma Europe Ltd. Overview

Astellas Pharma Europe Ltd. Health Check

ASTELLAS PHARMA EUROPE LTD. financials

astellas pharma europe ltd. Credit Report and Business Information

Astellas Pharma Europe Ltd. Competitor Analysis

astellas pharma europe ltd. Ownership

astellas pharma europe ltd. directors

astellas pharma europe ltd. company details

astellas pharma europe ltd. Charges & Mortgages

astellas pharma europe ltd. Capital Raised & Share Issues BETA

astellas pharma europe ltd. Companies House Filings - See Documents